Alamar Biosciences (ALMR) Q1 2026 earnings review
Triple-Digit Consumables Growth Validates Platform, IPO Secures Runway
Alamar Biosciences delivered a massive 99% YoY revenue jump to $26.0M in Q1 2026, fueled by a 178% surge in high-margin consumables. This favorable mix shift drove gross margins up 700 basis points to 56%. However, rapid scaling costs pushed operating losses to $12.3M, and an $8.6M convertible note remeasurement drove net loss to $21.3M. With a $198M net IPO completed in April, the balance sheet is fortified, removing near-term funding risks, though the delay of FY26 guidance to Q2 leaves a slight visibility gap for investors.
🐂 Bull Case
Consumables revenue growth (178%) dramatically outpaced instrument growth (78%), proving strong pull-through and high utilization of the expanding installed base.
Gross margin expanded from 49% to 56% as the company benefited from larger production volumes and a shift toward higher-margin consumables.
🐻 Bear Case
Despite revenue nearly doubling, absolute operating losses worsened by 44% to $12.3M as SG&A and R&D expenses surged to support commercial expansion.
An $8.6M non-operating loss on convertible notes severely impacted net income, pushing EPS to $(1.74) versus $(0.68) a year ago.
⚖️ Verdict: 🟢
Bullish. The explosive growth in consumables proves the underlying business model is highly scalable. The $198M IPO eliminates financial overhang, allowing the company to tolerate near-term cash burn as it aggressively captures market share.
Key Themes
Consumables Pull-Through Accelerating
Consumables revenue reached $14.0M, up 178% YoY, making it the largest contributor to the top line (54% of total revenue). This indicates that researchers are actively utilizing the NULISA instruments post-installation, supported by a slight increase in average selling prices.
NULISA Platform Expansion in Neuroscience
The company launched two highly specific new products: the NULISAseq Neuro 220 Panel and the NULISAqpcr AD 5-plex Assay. Expanding the menu of assays directly drives consumables growth and positions Alamar to capture increasing budgets in neurodegenerative disease research.
Gross Margin Leverage
Gross margin expanded to 56% from 49% in Q1 2025. Management attributed this to manufacturing efficiencies from larger volumes and favorable product mix. This trajectory is essential for the company to eventually outgrow its heavy operating expenses.
SG&A Spending Outpacing Profitability
While revenue grew 99%, the positive narrative is contradicted by worsening absolute profitability. SG&A surged 108% YoY to $13.8M—growing faster than revenue and completely consuming the $8.1M in incremental gross profit generated in the quarter. Scaling the commercial team is necessary, but the lack of near-term operating leverage is a risk.
Deferred Forward Visibility
Despite completing Q1 and finalizing a major IPO in April, management explicitly deferred providing full-year 2026 revenue guidance until August (Q2 earnings). This lack of forward visibility is unusual post-IPO and forces investors to model the remainder of the year blind.
Macro Exposure: Academic & Government Funding
The company remains highly dependent on researchers who rely on government funding. Any macro-driven reductions in spending by research and academic institutions could severely stall the current instrument placement momentum.
Other KPIs
Accelerating. Total operating expenses grew 79% YoY, driven by a 108% increase in SG&A ($13.8M) and a 57% increase in R&D ($13.0M). This heavy burn rate reflects aggressive commercial expansion and product development ahead of the IPO.
Stable/Strengthening. Q1 ended with $69.5M in cash, equivalents, and restricted cash. Adding the $197.8M in net IPO proceeds from April provides a massive capital cushion, completely transforming the balance sheet and funding multi-year operational runaways.
Guidance
Management intends to provide full-year 2026 revenue guidance in conjunction with its Q2 earnings release in August 2026. No short-term or full-year financial ranges were provided in this release.
Key Questions
Long-term Margin Targets
With gross margins expanding to 56% primarily due to consumables mix, what is the expected steady-state gross margin profile once the installed base matures?
Operating Leverage Timeline
SG&A more than doubled this quarter. At what revenue run-rate does management expect operating expenses to stabilize, allowing the company to narrow its absolute operating loss?
Guidance Delay Rationale
Why was full-year 2026 revenue guidance deferred to August, given that the Q1 books are closed and the IPO financing was successfully completed in April?